MPNUniversity.tv

Offering #Meded continuing education programs and the latest clinical advancements in myeloproliferative neoplasms (#MPNs) for #physicians and #nurses.

[MPNUniversity.tv @MPNUniversityTV]

Free CME program available on #ASCO17 Click the link to begin. https://t.co/4qdIWU0kl1 #MedEd #FOAMed #oncology #hematology @ASCO

[MPNUniversity.tv @MPNUniversityTV]

Alexander Lesokhin, MD, on the Potential of Immunotherapy for Myeloma https://t.co/UpMahnokFb via @CancerTherAdvsr

[Oncology.TV @oncologyTVfeed]

News & Views - Selective Inhibition of FLT3 by Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia: A Multicenter, First-in-human, Open Label, Phase 1-2 Study - pub. 11/14/17
https://t.co/4osv8wFRl6
#AMLOnTheGo #AML #BloodCancer

[MPNUniversity.tv @MPNUniversityTV]

The Molecular Genetics of Myeloproliferative Neoplasms from #SOHO2017
https://t.co/CdjW5EnliA #hematology #oncology #MPNs #meded #FOAMed

[MPNUniversity.tv @MPNUniversityTV]

Dr. Pollyea presents BCL-2 Inhibition in AML at #SOHO17. View here https://t.co/n7BiIone3w #AMLOntheGo @SocietyofHemOnc #bloodcancer #meded

[Oncology.TV @oncologyTVfeed]

#JustPublished Management of the Older Adult with #AML filmed at SOHO 2017@SocietyofHemOnc View here https://t.co/xow360mnih #AMLOntheGo

[MinuteCE @MinuteCE]

Introducing our first digital publication, AML On the Go
https://t.co/xN2LMkF4ie

#AMLOntheGo #AML #meded
https://t.co/1ZYq5zlhY8 #leukemia

[ASH @ASH_hematology]

Don't miss the free #AMLMATTERS summit in Philadelphia next month to earn CME https://t.co/vcpErF8pYS

[MPNUniversity.tv @MPNUniversityTV]

Introducing our first digital publication, AML On the Go
https://t.co/hVOjxTbs3w

#AMLOntheGo #AML #meded
https://t.co/iYedeE5cV1 #leukemia

[MPNUniversity.tv @MPNUniversityTV]

Follow https://t.co/QVnG1qmhY7 on Facebook for all your #mpn updates https://t.co/DLaChevQPk … #oncology #bloodcancer #cancer #meded

[MPNUniversity.tv @MPNUniversityTV]

Free CME program available from #ASCO17 Click the link to begin. https://t.co/4qdIWU0kl1 #MedEd #FOAMed #oncology #hematology @ASCOPost

[MPNUniversity.tv @MPNUniversityTV]

In #PV, Should JAK Inhibitor Therapy Be Restricted to After Failure of Hydroxyurea?

https://t.co/ijd89VgZe7 #MyeloproliferativeNeoplasms

[The ASCO Post @ASCOPost]

Karl D. Lewis, MD, on Melanoma: Results From the BRIM8 Trial https://t.co/yikfaLRNfA #ESMO17 #melsm #oncology

[MPNUniversity.tv @MPNUniversityTV]

FDA Approval of AML Therapy is a Significant Advance for Blood Cancer Patients https://t.co/LSkHWEi7jb #hematology

[Cancer Society of Maldives @CancerSocietyMV]

Day2:Facilitators training Health & Wellness and Cancer Awareness-School Health Officers(Atolls) @EducationMV @AFT_F #Nutrition #BloodCancer

[National Cancer Institute @theNCI]

The FDA approves a new formulation of rituximab (Rituxan™) for some patients with blood cancer: https://t.co/fiBq5bknna #lymphoma #leukemia

[MPNUniversity.tv @MPNUniversityTV]

Ublituximab and Ibrutinib for Previously Treated Genetically High-Risk CLL: GENUINE Study Results
https://t.co/dfty37ohPl #ASCO17 #ASCO

[MPNUniversity.tv @MPNUniversityTV]

WT1 Heteroclitic Epitope Immunization Following ASCT in Patients with High-Risk Multiple Myeloma from #ASCO 2017
https://t.co/dfty37ohPl #MM

[MPNUniversity.tv @MPNUniversityTV]

Perspectives and Future Directions in ET and PV: https://t.co/enOEABRVpL via @YouTube

[MPNUniversity.tv @MPNUniversityTV]

I added a video to a @YouTube playlist https://t.co/enOEAC9whj Perspectives and Future Directions in ET and PV

[MPNUniversity.tv @MPNUniversityTV]

Novel Agents and Combination Strategies in MF: https://t.co/PTZ1a8W5bQ via @YouTube